Drug Trial Radar · NCT05111626
Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.
Last checked: Nov 19, 2026Latest source record: Sep 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
515
Actual
Start
Mar 14, 2022
Primary completion
Oct 14, 2025
Study completion Oct 29, 2025
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- First posted
- Nov 8, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main objective of Part 1 is to evaluate the safety and tolerability of bemarituzumab plus 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) and nivolumab. The main objective Part 2 is to compare efficacy of bemarituzumab plus chemotherapy (mFOLFOX6 or capecitabine combined with oxaliplatin (CAPOX)) and nivolumab to placebo plus chemotherapy (mFOLFOX6 or CAPOX) and nivolumab as assessed by overall survival.
Conditions
- Gastric Cancer
- Gastroesophageal Junction Adenocarcinoma
Interventions
BemarituzumabDrug
Bemarituzumab will be administered as intravenous (IV) infusion.
NivolumabDrug
Nivolumab will be administered as IV infusion.
ChemotherapyDrug
mFOLFOX6: 5-fluorouracil, leucovorin, and oxaliplatin will be administered as IV infusion. OR CAPOX: oxaliplatin will be administered as IV infusion and capecitabine will be administered orally.
PlaceboOther
Placebo will be administered as IV infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Number of Participants Who Experienced DLTsTime frame: 28 days
- Part 1: Number of Participants Who Experienced One or More Treatment-Emergent Adverse Events (TEAEs)Time frame: Up to 4.5 years
- Part 1: Number of Participants Who Experienced One or More Related TEAEsTime frame: Up to 4.5 years
- Part 1: Number of Participants With Clinically Significant Changes in Vital SignsTime frame: Up to 4.5 years
- Part 1: Number of Participants With Clinically Significant Changes in Visual AcuityTime frame: Up to 4.5 years
- Part 1: Number of Participants With Clinically Significant Changes in Physical ExaminationsTime frame: Up to 4.5 years
- Part 1: Number of Participants with Clinically Significant Changes in Clinical Laboratory TestsTime frame: Up to 4.5 years
- Part 2: Overall Survival in FGFR2b ≥ 10% 2+/3+ Tumor Cell Staining ParticipantsTime frame: Up to 4.5 years
Locations
348 sites in 29 countries. Site status is shown where the registry gives one.
Mayo Clinic - Arizona
Phoenix, Arizona
The Oncology Institute Clinical Research
Cerritos, California
Cancer and Blood Specialty Clinic
Downey, California
City of Hope National Medical Center
Duarte, California
University of California Los Angeles
Los Angeles, California
University of California Irvine
Orange, California
Torrance Memorial Physician Network
Redondo Beach, California
Translational Research in Oncology - US Inc
Santa Monica, California
Translational Research in Oncology US Inc, Trio Central Pharmacy
Santa Monica, California
Olive View-University of California in Los Angeles Medical Center
Sylmar, California
Presbyterian Intercommunity Hospital Health Whitter Hospital
Whittier, California
Yale New Haven Hospital Yale Cancer Center
New Haven, Connecticut
Florida Cancer Specialists - Fort Myers
Fort Myers, Florida
Mayo Clinic
Jacksonville, Florida
Adventist Health System/Sunbelt, Inc d/b/a AdventHealth Orlando
Orlando, Florida
Orlando Health Cancer Institute
Orlando, Florida
University of Illinois Chicago
Chicago, Illinois
Greater Baltimore Medical Center
Baltimore, Maryland
Henry Ford Health System
Detroit, Michigan
Mayo Clinic
Rochester, Minnesota
Summit Medical Group
Florham Park, New Jersey
Memorial Sloan Kettering Cancer Center
New York, New York
Stony Brook University Medical Center
Stony Brook, New York
FirstHealth Cancer Center
Pinehurst, North Carolina
Gabrail Cancer Center, LLC
Canton, Ohio
Providence Cancer Institute Franz Clinic
Portland, Oregon
Saint Lukes University Health Network
Allentown, Pennsylvania
Medical University of South Carolina
Charleston, South Carolina
West Cancer Center
Germantown, Tennessee
Sarah Cannon Research Institute
Nashville, Tennessee
Texas Oncology Central-South
Austin, Texas
University of Texas MD Anderson Cancer Center
Houston, Texas
United States Oncology Regulatory Affairs Corporate Office
The Woodlands, Texas
US Oncology Research Investigational Products Center
The Woodlands, Texas
Virginia Oncology Associates
Norfolk, Virginia
Northwest Cancer Specialists - Vancouver
Vancouver, Washington
Aurora Health Care Metro Inc
Milwaukee, Wisconsin
Fundacion Respirar
Buenos Aires, Argentina
Hospital Italiano
Capital Federal, Argentina
Sanatorio Allende
Córdoba, Argentina
Showing 40 of 348 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.